Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ISAL 2019 | MDM2 inhibition in AML: trial updates

Marina Konopleva • 25 Feb 2019
ISAL 2019
Acute Myeloid Leukemia Leukemia Cytarabine Idasanutlin Venetoclax
MIRROS

The inhibition of MDM2 blocks the MDM2-p53 protein-protein interaction, allowing p53 to signal for apoptosis; however, there have been challenges with implementing this approach as a therapy. Here, Marina Konopleva, MD, PhD, of the University of Texas MD Anderson Cancer Center, Houston, TX, discusses the latest data regarding MDM2 inhibitor therapy for acute myeloid leukemia (AML); in combination with cytarabine (MIRROS; NCT02545283) or in combination with venetoclax (NCT02670044). This interview was recorded at the International Symposium on Acute Leukemias (ISAL) 2019, held in Munich, Germany.

Explore the AML Channel banner with headshots of Naval Daver, Eunice Wang, and Thomas Cluzeau

More from Marina Konopleva

Novel targets, combinations, and treatments in AML: insights from iwAL 2026
19:38
Novel targets, combinations, and treatments in AML: insights from iwAL 2026
Gail Roboz et al. • 7 Oct 2026
The value and mission of the International Workshop on Acute Leukemias
14:36
The value and mission of the International Workshop on Acute Leukemias
Charles Craddock et al. • 21 Oct 2025
iwAL 2025 highlights: resistance mechanisms in AML, novel targets, menin inhibitors & more
21:29
iwAL 2025 highlights: resistance mechanisms in AML, novel targets, menin inhibitors & more
Aditi Shastri et al. • 19 Sep 2025
Anti-tumor activity and hematopoietic restoration achieved with tagraxofusp in treatment-naïve BPDCN
1:48
Anti-tumor activity and hematopoietic restoration achieved with tagraxofusp in treatment-naïve BPDCN
Marina Konopleva • 13 Jun 2025

Related Videos

Unmet needs in CLL genomics: heterogeneity and clinical impact
1:11
Unmet needs in CLL genomics: heterogeneity and clinical impact
Elias Campo • 16 Oct 2026
Insights into key topics most likely to impact day-to-day CLL management
1:40
Insights into key topics most likely to impact day-to-day CLL management
Alessandra Ferrajoli • 16 Oct 2026
Translating current CLL evidence into national guidelines: which gaps remain?
3:33
Translating current CLL evidence into national guidelines: which gaps remain?
Mary Ann Anderson • 16 Oct 2026
Frontline management of Richter’s transformation: current approaches and remaining uncertainties
2:40
Frontline management of Richter’s transformation: current approaches and remaining uncertainties
Philip Thompson • 22 Oct 2026

Choose your cookie settings

VJHemOnc uses necessary cookies to make the site work. With your permission we'd also like to use analytics, preference and marketing cookies to understand how the site is used and improve it.

Choose an option to continue. You can change it at any time on our Cookie Policy page, linked at the bottom of every page.

Cookie Policy (opens in a new tab)
The content of VJHemOnc is intended for healthcare professionals